Ilaris

This page shows the latest Ilaris news and features for those working in and with pharma, biotech and healthcare.

Novartis withdraws EU filing for canakinumab

The decision is a further setback for this expansion in the use of canakinumab, which Novartis already markets as an inflammatory disease treatment under the brand name Ilaris.

Latest news

Novartis culls pipeline to focus on most transformative science

It recently hit problems with one of its most important late-stage programmes when the FDA refused to accept the filing of anti-inflammatory drug canakinumab (Ilaris) in cardiovascular risk reduction.
Daily Brief: EULAR kicks off, Brexit lurches closer and Autolus prepares for IPO

On today’s agenda expect new trial data from Novartis' Ilaris in gout, Lilly's Oluminant in systemic lupus and AbbVie's new JAK inhibitor upadacitinib.
CV data sets up Novartis' Ilaris for blockbuster sales

Drug shown to reduce major adverse cardiovascular events. Novartis has posted surprise phase III data that could transform the fortunes of its anti-inflammatory drug Ilaris, making it an option to ... The CANTOS study showed that the active ingredient in
Novartis' Ilaris wins three new FDA approvals

Immunotherapeutic expands in rare Periodic Fever Syndrome conditions. Novartis' anti-inflammatory therapy Ilaris (canakinumab) has received new US approvals for its use in three rare Periodic Fever Syndrome conditions. ... Paul Hudson, Novartis
Novartis wins childhood arthritis indication for Ilaris in EU

Novartis' inflammatory disease drug Ilaris (canakinumab) can be used more widely in the EU following its approval for the treatment of a rare form of childhood arthritis. ... The European Commission (EC) gave its final assent to Ilaris for the treatment

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

Latest appointments

AIMM Therapeutics appoints former Novartis VP Jan de Vries as CEO

During his time at Novartis, de Vries led the discovery and early development of several drugs including Elidel (pimecrolimus) for eczema, Ilaris (canakunimab) for cryopyrin-associated periodic syndromes, Gilenya (fingolimod) for

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer: Competitive salary and benefits

Director – Healthcare PR: Salary TBC

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Editor – Medical Education Agency – Bucks: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Medical Writer: Salary TBC

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Home-based Principal Medical Writer – Medical Comms: Salary TBC

Account Director, Medical Education: Salary TBC

PR Associate Director – Consumer Health & Beauty: Salary TBC

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Subscribe to our email news alerts

PMHub

Add my company

Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...